Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYN-AR-C is an oral homeopathic medicinal product developed by FUTRUE R&S 2 GmbH for the treatment of allergic rhinoconjunctivitis (hay fever) caused by grass pollen. It is part of a series of experimental formulations (including SYN-AR-A and SYN-AR-B) investigated in clinical trials to determine the optimal composition for symptom relief. The product utilizes homeopathic dilutions of natural substances to modulate the allergic response and alleviate symptoms such as sneezing, nasal congestion, and itchy eyes. In a Phase 2 randomized, placebo-controlled trial conducted in Germany, SYN-AR-C was evaluated for its efficacy and safety in patients with seasonal allergic rhinitis. The developer, FUTRUE, specializes in natural health and homeopathic OTC products, often utilizing proprietary complexes for respiratory and allergic conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SYN-AR-C.